NewsGlobeNewswire
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
· Published
Article summary
– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the fourth quarter of 2027 –
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…